When pet owners start tightening their belts, veterinary visits are often one of the first things to get cut. That's been the worry hanging over IDEXX Laboratories (NASDAQ: IDXX), the company that makes the diagnostic machines and test kits used in vet clinics worldwide. But the firm's latest quarterly results suggest those fears may be overblown.
IDEXX reported underlying revenue growth of 9% for the quarter, a measure that strips out currency swings and acquisitions. Earnings came in at $4.27 per share, comfortably beating the $3.96 analysts had expected. The company also raised its full-year earnings forecast to a range of $14.69 to $14.94 per share, up from its previous guidance of $14.45 to $14.90.
The beat is a clear sign that, despite a broader pullback in consumer spending, pet owners are still prioritizing their animals' health. "The results show that pet healthcare is a resilient category," said one analyst. "Even when people cut back on discretionary items, they tend to keep spending on their pets."
Why IDEXX matters
IDEXX is a leader in veterinary diagnostics, providing everything from blood analyzers to urine test kits. When a pet is sick, the vet relies on these tools to quickly identify the problem—whether it's an infection, kidney disease, or something else. The company's products are used in clinics around the world, making it a bellwether for the pet healthcare industry.
The company's business model is also attractive to investors. Once a clinic installs an IDEXX machine, it typically buys the consumables—test kits and reagents—on an ongoing basis. That recurring revenue stream provides a steady, predictable income, which is why the stock is often viewed as a defensive play in the healthcare sector.
But the recent environment has been challenging. With inflation squeezing household budgets, some pet owners have delayed routine checkups or skipped non-essential tests. That's why the latest results are so notable: they suggest the downturn in vet visits may be less severe than feared, and that IDEXX is managing to grow despite the headwinds.
What the numbers say
The 9% underlying revenue growth is particularly encouraging because it strips out the impact of currency fluctuations and acquisitions, giving a clearer picture of the company's organic performance. The earnings beat of $0.31 per share is also a strong signal that the company is managing costs effectively.
The raised guidance is another positive. By lifting the midpoint of its full-year earnings range, IDEXX is signaling that it expects the momentum to continue. That's a vote of confidence in the durability of pet healthcare spending, even as US consumer spending shows signs of holding up in other areas.
What it means for investors
For everyday investors, the key takeaway is that IDEXX's business is proving more resilient than the market had priced in. The stock had been under pressure as investors worried about a slowdown in vet visits, but the strong quarter suggests those concerns may be overdone.
That said, it's important to remember that past performance isn't a guarantee of future results. The pet healthcare market is competitive, and a prolonged economic downturn could still weigh on demand. But for now, IDEXX is showing that it has "plenty of bite"—and that its earnings power is stronger than many gave it credit for.
The company's ability to raise guidance also bodes well for the rest of the year. If the trend continues, IDEXX could be one of the more resilient names in the healthcare space, especially as other companies are also lifting their outlooks despite cautious spending.
The bigger picture
IDEXX's results come at a time when the broader economy is showing mixed signals. While some sectors are seeing a slowdown, others are holding up better than expected. The company's performance suggests that pet healthcare is one of those resilient pockets, much like Indonesia's growth beat despite cooling consumer spending.
For investors, the lesson is that not all consumer spending is created equal. While discretionary items like travel and dining out may suffer in a downturn, essential services—and even pet care—tend to be more stable. That's a useful reminder when building a diversified portfolio.
As always, it's wise to consider your own financial situation and risk tolerance before making any investment decisions. But for those looking for a company with steady demand and a track record of beating expectations, IDEXX is worth keeping on the radar.
